Immunic, Inc. (NASDAQ:IMUX) Given Average Rating of “Buy” by Analysts

Immunic, Inc. (NASDAQ:IMUX) has earned a consensus rating of “Buy” from the eleven ratings firms that are currently covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, six have given a buy rating and three have given a strong buy rating to the company. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $52.4286.

IMUX has been the topic of a number of recent analyst reports. D. Boral Capital lowered Immunic from a “buy” rating to a “hold” rating in a research note on Wednesday, April 15th. upgraded Immunic to a “strong-buy” rating in a research note on Tuesday, February 3rd. Wall Street Zen lowered Immunic from a “hold” rating to a “sell” rating in a research note on Sunday, April 19th. HC Wainwright reiterated a “buy” rating and issued a $22.00 target price (up from $5.00) on shares of Immunic in a research note on Thursday, April 30th. Finally, Lifesci Capital upgraded Immunic to a “strong-buy” rating in a research note on Monday, May 4th.

Immunic Stock Up 3.2%

IMUX stock opened at $12.00 on Tuesday. The business’s fifty day simple moving average is $11.31 and its two-hundred day simple moving average is $8.52. Immunic has a twelve month low of $5.06 and a twelve month high of $15.10. The firm has a market cap of $163.44 million, a price-to-earnings ratio of -1.71 and a beta of 1.20.

Immunic (NASDAQ:IMUX) last released its earnings results on Thursday, February 26th. The company reported ($1.20) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.02) by ($0.18). Research analysts expect that Immunic will post -3.44 EPS for the current year.

Hedge Funds Weigh In On Immunic

Several institutional investors have recently made changes to their positions in the company. Simplify Asset Management Inc. purchased a new position in shares of Immunic during the first quarter valued at $487,000. Seven Fleet Capital Management LP purchased a new position in shares of Immunic during the fourth quarter valued at $83,000. Connective Capital Management LLC purchased a new position in shares of Immunic during the fourth quarter valued at $161,000. XTX Topco Ltd purchased a new position in shares of Immunic during the fourth quarter valued at $120,000. Finally, Millennium Management LLC increased its stake in shares of Immunic by 544.6% during the fourth quarter. Millennium Management LLC now owns 3,419,299 shares of the company’s stock valued at $1,825,000 after buying an additional 2,888,829 shares during the period. Hedge funds and other institutional investors own 51.82% of the company’s stock.

Immunic Company Profile

Immunic, Inc is a clinical-stage biopharmaceutical company focused on developing novel oral therapies to treat chronic inflammatory and autoimmune diseases as well as certain cancers. The company’s research strategy centers on small-molecule immunology, aiming to offer targeted treatments with improved safety and tolerability profiles. By modulating key signaling pathways within the immune system, Immunic seeks to address underlying disease mechanisms and achieve durable therapeutic benefits for patients.

Immunic’s lead product candidate, vidofludimus calcium (IMU-838), is an oral selective dihydroorotate dehydrogenase (DHODH) inhibitor in Phase 2 clinical development for conditions including ulcerative colitis, Crohn’s disease and relapsing multiple sclerosis.